Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelizumab plus targeted therapy and chemotherapy for conversion of unresectable MSS colorectal cancer with liver metastases
ChiCTR2600122531Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebelizumab in colorectal adenocarcinoma, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 3-month conversion rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
adebelizumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600122531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122531.